KBC Group NV Sells 3,328 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

KBC Group NV lessened its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 26.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,069 shares of the biotechnology company’s stock after selling 3,328 shares during the quarter. KBC Group NV’s holdings in Axon Enterprise were worth $5,390,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Axon Enterprise by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after acquiring an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Axon Enterprise by 12.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC raised its stake in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after purchasing an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Axon Enterprise by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after purchasing an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment purchased a new position in shares of Axon Enterprise during the third quarter valued at approximately $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

AXON has been the topic of several recent analyst reports. Northland Securities raised their price objective on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Friday, November 8th. JMP Securities increased their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. TD Cowen assumed coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. Finally, Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $524.85.

Insider Transactions at Axon Enterprise

In other news, Director Julie A. Cullivan sold 1,261 shares of Axon Enterprise stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total value of $860,077.66. Following the completion of the transaction, the director now directly owns 2,392 shares in the company, valued at approximately $1,631,487.52. The trade was a 34.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,545 shares of company stock worth $30,721,337 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Axon Enterprise Trading Up 2.1 %

Shares of Axon Enterprise stock opened at $653.43 on Friday. The stock has a market capitalization of $49.82 billion, a P/E ratio of 168.85, a P/E/G ratio of 6.09 and a beta of 1.04. Axon Enterprise, Inc. has a 52-week low of $247.04 and a 52-week high of $698.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The stock’s 50-day simple moving average is $619.32 and its 200 day simple moving average is $479.00.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.